Purpose: Recent evidence supports the efficacy of scalp cooling in preventing chemotherapy-induced alopecia in breast cancer treatments. However, efficacy largely varies between treatment regimens. The aim of this study was to explore the patient- and nurse-reported results of scalp cooling in terms of hair loss and need for a wig/head cover in patients with breast cancer treated with 3-weekly docetaxel 75 mg/m- cyclophosphamide 600 mg/m.
Methods: We studied nurse-reported efficacy as noted in the electronic patient files of 85 patients treated with docetaxel 75 mg/m- cyclophosphamide 600 mg/m between 1/1/2017 and 1/1/2020. Sixty-nine of them also self-reported on their scalp cooling results up to one year after adjuvant chemotherapy in a retrospective way.
Results: Nurse- and patient-reported data showed that scalp cooling was successful (i.e., hair loss < 50%) in 47.1 and 44.9% of patients, respectively, and 55% of patients were (very) satisfied with the result of scalp cooling. Scalp cooling was perceived as (very) uncomfortable in 36.2% of patients. Regarding hair status one year after treatment, 47 patients (55.3%) reported no changes compared to their hair status before treatment.
Conclusions: Scalp cooling is successful in preventing severe chemotherapy-induced alopecia in almost half of the patients with breast cancer treated with docetaxel 75 mg/m- cyclophosphamide 600 mg/m. Better understanding of the success rate of scalp cooling enables correct patient information and decision-making support.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10549-020-06063-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evolution of long scalp hair in humans.
Br J Dermatol
January 2025
Department of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei, Taiwan.
The ability to grow long scalp hair is a distinct human characteristic. It probably originally evolved to aid in cooling the sun-exposed head, although the genetic determinants of long hair are largely unknown. Despite ancestral variations in hair growth, long scalp hair is common to all extant human populations, which suggests its emergence before or concurrently with the emergence of anatomically modern humans (AMHs), approximately 300 000 years ago.
View Article and Find Full Text PDFUse of scalp cooling therapy in patients with breast or gynecological cancers undergoing chemotherapy may be associated with a higher risk of systemic recurrence.
Support Care Cancer
January 2025
MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800, Ankara, Turkey.
Fucoidan treats chemotherapy-induced alopecia and helps cyclophosphamide treat tumors.
Int J Biol Macromol
January 2025
College of Chemical Engineering, Huaqiao University, Xiamen, Fujian 361021, China; Xiamen Engineering and Technological Research Center for Comprehensive Utilization of Marine Biological Resources, Xiamen 361021, China.
Chemotherapy-induced alopecia (CIA) represents one of the most common side effects of cancer treatment. Currently, scalp cooling systems are utilized to treat CIA, but their safety and effectiveness remain limited. The objective of this study was to investigate the effect of fucoidan on CIA and to elucidate the possible mechanism of fucoidan in treating CIA.
View Article and Find Full Text PDFScalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers-an Asian tertiary institution experience.
Support Care Cancer
November 2024
Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore.
Purpose: Scalp cooling therapy (SCT) improves chemotherapy-induced alopecia (CIA), but there are few published data about its efficacy in an Asian-predominant population. We report our tertiary institution experience of SCT in patients with breast or gynaecological cancers undergoing chemotherapy.
Methods: The Paxman scalp cooling system was employed for eligible women with breast or gynaecological cancers receiving anthracycline or taxane-based chemotherapy.
tDCS and local scalp cooling do not change corticomotor and intracortical excitability in healthy humans.
Clin Neurophysiol
December 2024
Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil.
Article Synopsis
- The study aimed to determine if scalp cooling can enhance the effects of transcranial direct current stimulation (tDCS) on motor cortex excitability.
- It involved 105 healthy participants in a randomized, double-blind design where various tDCS protocols and scalp cooling were tested, with motor evoked potentials measured to assess changes in brain excitability.
- Results indicated that neither tDCS nor scalp cooling produced measurable improvements in motor cortex excitability, suggesting that these methods do not alter cortical excitability effectively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!